Skip to main content
OpenTrials
Completed

NCT Number: NCT02777424

CPP Versus PFC to Correct Coagulation Disorders in Adult Neurosurgical Patients

This prospective, randomized, multicenter study is performed to determine whether prothrombin complex concentrates confers any benefits over fresh frozen plasma in adult neurological patients with coagulation disorders (PT value less than 60%).

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

CHU de Lille, Lille, France

Loading trial locations.

About this study

The coagulation disorders increase the risk of bleeding and are a risk factor of intracranial hemorrhagic complications in neurosurgical patients. They are diagnosed more often in emergency on a PT value less than 60% and so they should be corrected as soon as possible. Two therapeutic strategies are proposed by French or international recommendations: transfusion of fresh frozen plasma (FFP) or administration of prothrombin complex concentrates (PCC).

This prospective, randomized, multicenter study with blinded assessment of the primary endpoint, is performed to determine whether PCC confers any benefits over FFP in the neurological patients with coagulation disorders.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient with spontaneous intracranial hemorrhage or traumatic intracranial hemorrhage or patient requiring neurological surgery
  • Coagulation disorder defined by PT less than 60%

Exclusion criteria

  • Concomitant use with oral anticoagulant drugs
  • Acquired deficiency of coagulation factors whose treatment is established
  • Hypersensitivity to a PCC
  • History of thrombocytopenia induced by heparin
  • Disseminated intravascular coagulation
  • Extracranial active bleeding
  • Hypersensitivity to vitamin K

Treatment and study plan

Prothrombin Complex Concentrate

Drug

Non-activated prothrombin complex concentrate containing factors II, VII, IX and X and proteins C & S

fresh frozen plasma

Biological

Pooled collection of plasma from donors

Primary outcomes

  1. Proportion of patients with correction of prothrombin time (PT more than 60%)

    Time frame: End of treatment administration (an average of 1 hour)

Sponsors and collaborators

Lead sponsor

Fondation Ophtalmologique Adolphe de Rothschild

Network

Registry information

Official study title

Prothrombin Complex Concentrate Versus Fresh Frozen Plasma to Correct Coagulation Disorders in Adult Neurosurgical Patients

Acronym: CLOT-CRANE

Important dates

Study start
2016
Primary completion
2019
Study completion
2019
First posted
May 19, 2016
Registry last updated
Jun 5, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.